Shanghai-based biotechnology company developing antibody-drug conjugates (ADCs) for immunology and oncology
Shanghai-based biotechnology company developing antibody-drug conjugates (ADCs) for immunology and oncology. Its lead candidate, LYNC-101, targets activated immune cells and delivers a non-steroid immunomodulatory payload for inflammatory bowel disease; it has entered Phase 1 clinical testing.